{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:57Z","timestamp":1786980297160,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00520-026-10691-1","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:16:39Z","timestamp":1776665799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonists during chemotherapy and radiotherapy: a supportive care call for nutrition-centred monitoring in the era of widespread prescribing"],"prefix":"10.1007","volume":"34","author":[{"given":"Aur\u00e9lia","family":"Alati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"11","key":"10691_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"10691_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3","author":"B Calvarysky","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen T (2024) Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf. https:\/\/doi.org\/10.1007\/s40264-023-01392-3","journal-title":"Drug Saf"},{"key":"10691_CR3","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.2147\/DDDT.S506957","volume":"19","author":"JS Min","year":"2025","unstructured":"Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB et al (2025) A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist. Drug Des Devel Ther 19:3509\u201337. https:\/\/doi.org\/10.2147\/DDDT.S506957","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10691_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"issue":"24","key":"10691_CR5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"issue":"19","key":"10691_CR6","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"10193","key":"10691_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"4","key":"10691_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"5","key":"10691_CR9","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH et al (2025) Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 27(5):2720\u20139. https:\/\/doi.org\/10.1111\/dom.16275","journal-title":"Diabetes Obes Metab"},{"key":"10691_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS (2025) Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism 164:156113. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113","journal-title":"Metabolism"},{"key":"10691_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110663","volume":"203","author":"AJ Vickers","year":"2025","unstructured":"Vickers AJ, McSweeney DM, Choudhury A, Weaver J, Price G, McWilliam A (2025) The prognostic significance of sarcopenia in patients treated with definitive radiotherapy: a systematic review. Radiother Oncol 203:110663. https:\/\/doi.org\/10.1016\/j.radonc.2024.110663","journal-title":"Radiother Oncol"},{"issue":"6","key":"10691_CR12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/hed.27688","volume":"46","author":"MA Mascarella","year":"2024","unstructured":"Mascarella MA, Ferdus J, Vendra V, Sridharan S, Sultanem K, Tsien C et al (2024) Sarcopenia predicts short-term treatment-related toxicity in patients undergoing curative-intent therapy for head and neck cancer: a systematic review and meta-analysis. Head Neck 46(6):1500\u20139. https:\/\/doi.org\/10.1002\/hed.27688","journal-title":"Head Neck"},{"issue":"9","key":"10691_CR13","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1245\/s10434-024-15510-7","volume":"31","author":"JH Koh","year":"2024","unstructured":"Koh JH, Lim CYJ, Tan LTP, Makmur A, Gao EY, Ho JSY et al (2024) Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: a systematic review and meta-analysis. Ann Surg Oncol 31(9):6049\u201364. https:\/\/doi.org\/10.1245\/s10434-024-15510-7","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10691_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA (2024) GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity. JAMA Oncol 10(2):256\u2013258. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5573","journal-title":"JAMA Oncol"},{"key":"10691_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107401","volume":"208","author":"G Figlioli","year":"2024","unstructured":"Figlioli G, Piovani D, Peppas S, Pugliese N, Hassan C, Repici A et al (2024) Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 208:107401. https:\/\/doi.org\/10.1016\/j.phrs.2024.107401","journal-title":"Pharmacol Res"},{"issue":"1","key":"10691_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169","journal-title":"Age Ageing"},{"issue":"1","key":"10691_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36(1):11\u201348. https:\/\/doi.org\/10.1016\/j.clnu.2016.07.015","journal-title":"Clin Nutr"},{"issue":"3","key":"10691_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092","volume":"6","author":"J Arends","year":"2021","unstructured":"Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P et al (2021) Cancer cachexia in adult patients: ESMO clinical practice guidelines\u2606. ESMO Open 6(3):100092. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100092","journal-title":"ESMO Open"},{"issue":"5","key":"10691_CR19","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","volume":"40","author":"M Muscaritoli","year":"2021","unstructured":"Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H et al (2021) ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr 40(5):2898\u2013913. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.005","journal-title":"Clin Nutr"},{"key":"10691_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2024.112526","volume":"128","author":"F Wang","year":"2024","unstructured":"Wang F, Xiao J, Wang Q, Zhen H, Liu Z, Yu K (2024) Identifying low muscle mass and monitoring body composition changes in newly diagnosed cancer patients: agreement between multifrequency bioelectrical impedance analysis and computed tomography. Nutrition 128:112526. https:\/\/doi.org\/10.1016\/j.nut.2024.112526","journal-title":"Nutrition"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10691-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10691-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10691-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:48:40Z","timestamp":1778683720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10691-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10691"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10691-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"447"}}